Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R
Department of Obstetrics and Gynecology, University of Graz, Auenbruggerplatz 14, Graz, A-8036, Austria.
Gynecol Oncol. 2000 Mar;76(3):331-5. doi: 10.1006/gyno.1999.5700.
The purpose of this research was to compare the clinical behavior, pathology findings, and prognosis of surgically treated FIGO stage IB-IIB clear cell carcinomas of the cervix with those of squamous cell carcinomas and non-clear cell adenocarcinomas.
Fifteen patients with clear cell adenocarcinomas of the cervix (8 FIGO stage IB, 7 FIGO stage IIB) were reviewed. The control group consisted of 444 squamous cell carcinomas and 59 non-clear cell adenocarcinomas. None of the patients had a history of in utero exposure to diethylstilbestrol. All patients underwent radical abdominal hysterectomy with systematic pelvic lymphadenectomy. All specimens were processed as serial giant frontal sections. The mean follow-up in the clear cell group was 83 (13-182) months. Statistical analysis was done with contingency tables, chi(2) tests, and Fisher's exact test.
Twelve of the fifteen clear cell carcinomas (80%) were endophytic and tended toward deep cervical infiltration. Clear cell carcinomas extended to the uterine corpus significantly more often than squamous cell and non-clear cell adenocarcarcinomas (P < 0.001). The rates of parametrial involvement and pelvic lymph node involvement were 40 and 47%, respectively. Four patients (27%), all with positive pelvic nodes, developed recurrences an average of 14 (4-48) months after initial therapy. The extrapelvic sites of relapse were the lung, liver, and bone. Clear cell carcinomas had a worse 5-year survival rate (67%) than squamous cell carcinomas (80%) and non-clear cell adenocarcinomas (77%) but this was not statistically significant (P = 0.6). No significant differences were seen for age, growth pattern, parametrial and vaginal involvement, parametrial and pelvic lymph node metastases, frequency of recurrent disease, and time to first recurrence.
The clinicopathologic findings and prognosis of surgically treated patients with stage IB-IIB clear cell carcinomas without exposure to diethylstilbestrol in utero are similar to those of patients with squamous cell carcinomas and non-clear cell adenocarcinomas.
本研究旨在比较手术治疗的国际妇产科联盟(FIGO)IB-IIB期宫颈透明细胞癌与鳞状细胞癌及非透明细胞腺癌的临床行为、病理结果和预后。
回顾了15例宫颈透明细胞腺癌患者(8例FIGO IB期,7例FIGO IIB期)。对照组包括444例鳞状细胞癌和59例非透明细胞腺癌。所有患者均无宫内接触己烯雌酚的病史。所有患者均接受了根治性腹式子宫切除术及系统性盆腔淋巴结清扫术。所有标本均制成连续的巨大额状切片。透明细胞癌组的平均随访时间为83(13 - 182)个月。采用列联表、卡方检验和Fisher精确检验进行统计学分析。
15例透明细胞癌中有12例(80%)为内生型,倾向于宫颈深部浸润。透明细胞癌扩展至子宫体的频率显著高于鳞状细胞癌和非透明细胞腺癌(P < 0.001)。宫旁组织受累率和盆腔淋巴结受累率分别为40%和47%。4例患者(27%)均有盆腔淋巴结阳性,在初始治疗后平均14(4 - 48)个月出现复发。盆腔外复发部位为肺、肝和骨。透明细胞癌的5年生存率(67%)低于鳞状细胞癌(80%)和非透明细胞腺癌(77%),但差异无统计学意义(P = 0.6)。在年龄、生长方式、宫旁组织和阴道受累情况、宫旁组织和盆腔淋巴结转移、复发疾病频率以及首次复发时间方面未见显著差异。
对于宫内未接触己烯雌酚的手术治疗的IB-IIB期透明细胞癌患者,其临床病理结果和预后与鳞状细胞癌及非透明细胞腺癌患者相似。